The Food and Drug Administration (FDA) has approved Encelto ™ (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia type 2 (MacTel). MacTel is a rare, progressive eye disease that ...

1.Charbel Issa P, Gillies MC, Chew EY, Heeren TFC, Bird AC, Peto T, Holz FG, Scholl HPN (2013) Macular Telangiectasia Type 2. La Merie Publishing offers the service of preparing customized reports ...

Revakinagene taroretcel-lwey is the first FDA-approved treatment for macular telangiectasia type 2, a progressive neurodegenerative retinal disease. The therapy uses an encapsulated cell-based ...

for the treatment of Macular Telangiectasia type 2 (MacTel). MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly ...

Encelto is the first FDA-approved treatment for macular telangiectasia type 2. The cell therapy slows the loss of macular photoreceptors through continuous delivery of ciliary neurotrophic factor.

Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved ...

The US Food and Drug Administration (FDA) has approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals for the treatment of Macular Telangiectasia type 2 (MacTel). At the date of ...

Macular Telangiectasia Type 2 (MacTel), or idiopathic macular telangiectasia type 2, is a bilateral, neurodegenerative disease in adults with characteristic localized retinal degeneration, a group of ...